Journal article 322 views
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
Axel Bex,
Peter Mulders,
Michael Jewett,
John Wagstaff,
Johannes V. van Thienen,
Christian U. Blank,
Roland van Velthoven,
Maria del Pilar Laguna,
Lori Wood,
Harm H. E. van Melick,
Maureen J. Aarts,
J. B. Lattouf,
Thomas Powles,
Igle Jan de Jong, MD, PhD,
Sylvie Rottey,
Bertrand Tombal,
Sandrine Marreaud,
Sandra Collette,
Laurence Collette,
John Haanen
JAMA Oncology, Volume: 5, Issue: 2, Start page: 164
Swansea University Author: John Wagstaff
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1001/jamaoncol.2018.5543
Abstract
This was a randomised phase II trial of immediate versus deferred nephrectomy in patients who were diagnosed with metastatic renal cancer with the primary cancer still in situ. Patients were randomised to have and up-front nephrectomy followed by sunitinib or three cycles of sunitinib followed by ne...
| Published in: | JAMA Oncology |
|---|---|
| ISSN: | 2374-2437 |
| Published: |
2019
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa50641 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
This was a randomised phase II trial of immediate versus deferred nephrectomy in patients who were diagnosed with metastatic renal cancer with the primary cancer still in situ. Patients were randomised to have and up-front nephrectomy followed by sunitinib or three cycles of sunitinib followed by nephrectomy. Patients continued sunitinib after nephrectomy. Deferred nephrectomy did not improve the 28 week progression free rate. However the median survival of the patients in the deferred nephrectomy arm was 32.4 months in the deferred nephrectomy arm and 15 months in the immediate nephrectomy arm. These data suggest that sunitinib followed by deferred nephrectomy may identify a group of patients with inherent resistance to systemic therapy and who do not benefit from immediate nephrectomy. |
|---|---|
| Item Description: |
The author was UK principle investigator for this clinical trial. |
| Keywords: |
renal cancer, sunitinib, nephrectomy |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
2 |
| Start Page: |
164 |